A two arm, randomized, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension (DLS) for Injection of Intas Pharmaceuticals Limited, India in Non-Small Cell Lung Cancer patients. - NA

Trial Profile

A two arm, randomized, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension (DLS) for Injection of Intas Pharmaceuticals Limited, India in Non-Small Cell Lung Cancer patients. - NA

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Intas Pharmaceuticals
  • Most Recent Events

    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top